ESTIMATING UTILITIES FOR HEALTH STATES ASSOCIATED WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP) USING EQ-5D-5L AND TIME TRADE-OFF METHODOLOGIES
Author(s)
Elin Gruffydd, MSc1, Bhovina Buguth, MSc2, Michael Watt, PhD2, Paul Macleod, BSc, MSc2, Sonia Shpendi, PhD1, Millie Gaydon, BSc1, Andrew Lloyd, DPhil1, Claire Lawrence, MSc, PhD1.
1Acaster Lloyd, London, United Kingdom, 2AstraZeneca UK Ltd, London, United Kingdom.
1Acaster Lloyd, London, United Kingdom, 2AstraZeneca UK Ltd, London, United Kingdom.
OBJECTIVES: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory condition of the paranasal sinuses which can substantially impair patients’ health-related quality of life (HRQoL). This study aimed to develop and validate health state vignettes for CRSwNP and estimate associated utility values.
METHODS: Draft health state vignettes were informed by a targeted literature review and analysis of patient HRQoL data. Six health states were defined by surgery history (1 surgery vs ≥2 surgeries) and disease severity based on Sino-Nasal Outcome Test score (SNOT-22; mild=≤20, moderate=21-50, severe= >50). Draft vignettes were validated and refined through cognitive debriefing interviews with clinicians (N=5) and patients (N=10) assessing relevance, clarity, and completeness. Final vignettes were valued by members of the general public (N=100) and patients (N=36), using two methods: an online survey obtaining EQ-5D-5L valuations, and online one-to-one Time Trade-Off interviews (TTO).
RESULTS: Utility values were broadly similar between the general public and patient samples; however, the EQ-5D-5L-derived utilities were lower than the TTO utilities for moderate and severe health states. Utilities decreased with increasing disease severity; the lowest values were observed for the ‘≥2 Surgeries, Severe’ health state (general public EQ-5D-5L = 0.343, patient EQ-5D-5L = 0.386, general public TTO = 0.565, patient TTO = 0.579). The highest utility values were observed for mild health states (e.g. ‘1 Surgery, Mild’ health state: general public EQ-5D-5L = 0.937, patient EQ-5D-5L = 0.921, general public TTO = 0.949, patient TTO = 0.965).
CONCLUSIONS: Findings demonstrate the substantial HRQoL impact of CRSwNP, with lower utilities observed for more severe health states. Similar estimates across patient and general public samples support the credibility of the vignettes. Differences between the EQ-5D-5L- and TTO- derived utilities suggest that utility estimates are sensitive to the valuation method; therefore, the valuation approach and plausibility of very low utilities should be considered carefully in economic evaluations.
METHODS: Draft health state vignettes were informed by a targeted literature review and analysis of patient HRQoL data. Six health states were defined by surgery history (1 surgery vs ≥2 surgeries) and disease severity based on Sino-Nasal Outcome Test score (SNOT-22; mild=≤20, moderate=21-50, severe= >50). Draft vignettes were validated and refined through cognitive debriefing interviews with clinicians (N=5) and patients (N=10) assessing relevance, clarity, and completeness. Final vignettes were valued by members of the general public (N=100) and patients (N=36), using two methods: an online survey obtaining EQ-5D-5L valuations, and online one-to-one Time Trade-Off interviews (TTO).
RESULTS: Utility values were broadly similar between the general public and patient samples; however, the EQ-5D-5L-derived utilities were lower than the TTO utilities for moderate and severe health states. Utilities decreased with increasing disease severity; the lowest values were observed for the ‘≥2 Surgeries, Severe’ health state (general public EQ-5D-5L = 0.343, patient EQ-5D-5L = 0.386, general public TTO = 0.565, patient TTO = 0.579). The highest utility values were observed for mild health states (e.g. ‘1 Surgery, Mild’ health state: general public EQ-5D-5L = 0.937, patient EQ-5D-5L = 0.921, general public TTO = 0.949, patient TTO = 0.965).
CONCLUSIONS: Findings demonstrate the substantial HRQoL impact of CRSwNP, with lower utilities observed for more severe health states. Similar estimates across patient and general public samples support the credibility of the vignettes. Differences between the EQ-5D-5L- and TTO- derived utilities suggest that utility estimates are sensitive to the valuation method; therefore, the valuation approach and plausibility of very low utilities should be considered carefully in economic evaluations.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR87
Topic
Economic Evaluation, Patient-Centered Research, Study Approaches
Topic Subcategory
Health State Utilities
Disease
Biologics & Biosimilars, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)